Your browser doesn't support javascript.
loading
Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection.
Semmes, Eleanor C; Miller, Itzayana G; Wimberly, Courtney E; Phan, Caroline T; Jenks, Jennifer A; Harnois, Melissa J; Berendam, Stella J; Webster, Helen; Hurst, Jillian H; Kurtzberg, Joanne; Fouda, Genevieve G; Walsh, Kyle M; Permar, Sallie R.
Afiliação
  • Semmes EC; Medical Scientist Training Program, Department of Molecular Genetics and Microbiology and.
  • Miller IG; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Wimberly CE; Duke Children's Health & Discovery Initiative, Duke University, Durham, North Carolina, USA.
  • Phan CT; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Jenks JA; Department of Pediatrics, Weill Cornell School of Medicine, New York, New York, USA.
  • Harnois MJ; Duke Children's Health & Discovery Initiative, Duke University, Durham, North Carolina, USA.
  • Berendam SJ; Department of Neurosurgery and.
  • Webster H; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Hurst JH; Medical Scientist Training Program, Department of Molecular Genetics and Microbiology and.
  • Kurtzberg J; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Fouda GG; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Walsh KM; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
  • Permar SR; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
J Clin Invest ; 132(16)2022 08 15.
Article em En | MEDLINE | ID: mdl-35763348
ABSTRACT
Human cytomegalovirus (HCMV) is the most common congenital infection and a leading cause of stillbirth, neurodevelopmental impairment, and pediatric hearing loss worldwide. Development of a maternal vaccine or therapeutic to prevent congenital HCMV has been hindered by limited knowledge of the immune responses that protect against HCMV transmission in utero. To identify protective antibody responses, we measured HCMV-specific IgG binding and antiviral functions in paired maternal and cord blood sera from HCMV-seropositive transmitting (n = 41) and non-transmitting (n = 40) mother-infant dyads identified via a large, US-based, public cord blood bank. We found that high-avidity IgG binding to HCMV and antibody-dependent cellular phagocytosis (ADCP) were associated with reduced risk of congenital HCMV infection. We also determined that HCMV-specific IgG activation of FcγRI and FcγRII was enhanced in non-transmitting dyads and that increased ADCP responses were mediated through both FcγRI and FcγRIIA expressed on human monocytes. These findings suggest that engagement of FcγRI/FcγRIIA and Fc effector functions including ADCP may protect against congenital HCMV infection. Taken together, these data can guide future prospective studies on immune correlates against congenital HCMV transmission and inform HCMV vaccine and immunotherapeutic development.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Citomegalovirus / Infecções por Herpesviridae / Vacinas contra Citomegalovirus Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Citomegalovirus / Infecções por Herpesviridae / Vacinas contra Citomegalovirus Idioma: En Ano de publicação: 2022 Tipo de documento: Article